ImmuPharma (LON:IMM) Shares Down 8.3% – Should You Sell?

Shares of ImmuPharma plc (LON:IMMGet Free Report) were down 8.3% during trading on Wednesday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.59 ($0.06). Approximately 7,864,863 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 22,321,723 shares. The stock had previously closed at GBX 5 ($0.06).

ImmuPharma Stock Down 4.9 %

The stock has a 50 day moving average of GBX 2.34 and a 200 day moving average of GBX 1.91. The firm has a market cap of £17.87 million, a price-to-earnings ratio of -429.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.